News Website

FDA grants breakthrough designation for Acrivon’s endometrial cancer assay - Yahoo! Voices

FDA grants breakthrough designation for Acrivon’s endometrial cancer assay Yahoo! Voices

Published: Feb. 6, 2025, 9:54 a.m.

Read Full Article

ASCO Reading Room | Is the End of Systemic Chemotherapy Near for Advanced Endometrial Cancer? - Medpage Today

ASCO Reading Room | Is the End of Systemic Chemotherapy Near for Advanced Endometrial Cancer? Medpage Today

Published: Feb. 5, 2025, 7:31 p.m.

Read Full Article

Christian Marth on a First-Line Chemotherapy-Free Option for Advanced Endometrial Cancer - Medpage Today

Christian Marth on a First-Line Chemotherapy-Free Option for Advanced Endometrial Cancer Medpage Today

Published: Feb. 5, 2025, 5:54 p.m.

Read Full Article

First-Line Lenvatinib Plus Pembrolizumab Versus Chemotherapy for Advanced Endometrial Cancer: A Randomized, Open-Label, Phase III Trial - Medpage Today

First-Line Lenvatinib Plus Pembrolizumab Versus Chemotherapy for Advanced Endometrial Cancer: A Randomized, Open-Label, Phase III Trial Medpage Today

Published: Feb. 5, 2025, 5:54 p.m.

Read Full Article

FDA Grants Breakthrough Device Designation to ACR-368 OncoSignature Assay for Endometrial Cancer - OncLive

FDA Grants Breakthrough Device Designation to ACR-368 OncoSignature Assay for Endometrial Cancer OncLive

Published: Feb. 5, 2025, 5:17 p.m.

Read Full Article

A Case of Postoperative Lymphatic Ascites in Endometrial Cancer Spontaneously Resolving After Approximately One Year of Watchful Waiting - Cureus

A Case of Postoperative Lymphatic Ascites in Endometrial Cancer Spontaneously Resolving After Approximately One Year of Watchful Waiting Cureus

Published: Feb. 5, 2025, 1:26 p.m.

Read Full Article

Acrivon Therapeutics Announces FDA has Granted Breakthrough Device Designation for ACR-368 OncoSignature Assay for Endometrial Cancer - The Manila Times

Acrivon Therapeutics Announces FDA has Granted Breakthrough Device Designation for ACR-368 OncoSignature Assay for Endometrial Cancer The Manila Times

Published: Feb. 5, 2025, 1:07 p.m.

Read Full Article

Targeting the splicing factor SNRPB inhibits endometrial cancer progression by retaining the POLD1 intron - Nature.com

Targeting the splicing factor SNRPB inhibits endometrial cancer progression by retaining the POLD1 intron Nature.com

Published: Feb. 5, 2025, 11:37 a.m.

Read Full Article

Survival Outcomes in Advanced Endometrial Cancer with Lenvatinib plus Pembrolizumab - Physician's Weekly

Survival Outcomes in Advanced Endometrial Cancer with Lenvatinib plus Pembrolizumab Physician's Weekly

Published: Feb. 4, 2025, 11:09 a.m.

Read Full Article

Judge Indicates 40 Hair Relaxer Lawsuits Over Uterine Cancer, Endometrial Cancer and Ovarian Cancer Will Be Selected for Early Trial Program - AboutLawsuits.com

Judge Indicates 40 Hair Relaxer Lawsuits Over Uterine Cancer, Endometrial Cancer and Ovarian Cancer Will Be Selected for Early Trial Program AboutLawsuits.com

Published: Feb. 3, 2025, 9:15 p.m.

Read Full Article

Latest Articles

FDA grants breakthrough designation for Acrivon’s endometrial cancer assay - Yahoo! Voices

ASCO Reading Room | Is the End of Systemic Chemotherapy Near for Advanced Endometrial Cancer? - Medpage Today

Christian Marth on a First-Line Chemotherapy-Free Option for Advanced Endometrial Cancer - Medpage Today

First-Line Lenvatinib Plus Pembrolizumab Versus Chemotherapy for Advanced Endometrial Cancer: A Randomized, Open-Label, Phase III Trial - Medpage Today

FDA Grants Breakthrough Device Designation to ACR-368 OncoSignature Assay for Endometrial Cancer - OncLive

A Case of Postoperative Lymphatic Ascites in Endometrial Cancer Spontaneously Resolving After Approximately One Year of Watchful Waiting - Cureus

Acrivon Therapeutics Announces FDA has Granted Breakthrough Device Designation for ACR-368 OncoSignature Assay for Endometrial Cancer - The Manila Times

Targeting the splicing factor SNRPB inhibits endometrial cancer progression by retaining the POLD1 intron - Nature.com

Survival Outcomes in Advanced Endometrial Cancer with Lenvatinib plus Pembrolizumab - Physician's Weekly

Judge Indicates 40 Hair Relaxer Lawsuits Over Uterine Cancer, Endometrial Cancer and Ovarian Cancer Will Be Selected for Early Trial Program - AboutLawsuits.com

Subscribe to Our Newsletter